35 /100
MEDIUM RISK
Score updated Jul 14, 2026

IBRX — ImmunityBio, Inc. Dilution Risk Tracker

Track IBRX dilution risk with DilutionWatch's stock tracker. DilutionScore™ measures dilution risk across 5 factors — lower scores indicate higher risk of share dilution.

⚠️ Not financial advice. Do your own research before making any investment decisions.

🔔 Track IBRX — Get alerts when the score changes →

As of July 14, 2026, ImmunityBio, Inc. (IBRX) has a DilutionWatch DilutionScore of 35/100, rated MEDIUM dilution risk. ImmunityBio, Inc. has a market capitalization of $7.88B, 1.05B shares outstanding, 396 institutional holders tracked. Key dilution vectors include approximately 13 months of cash runway.

Source: DilutionWatch (dilutionwatch.com) — data updated daily from SEC EDGAR filings. Not financial advice.

📊 Score Breakdown

📋 Offering Ability
32
💰 Cash Runway
40
📊 Float Risk
67
⚠️ Warrant Exposure
15
🔄Convertible Debt—

🌦️ Dilution Forecast

☀️
Clear
No significant dilution signals
0%
No significant dilution signals detected for IBRX.
🔔 Track IBRX — Get forecast alerts →

💹 Market Data

Market Cap$7.88B
Shares Outstanding1.05B
Float394.04M
Cash$380.88M
Debt$884.0K
Short InterestN/A

🏛 Institutional Holdings

QoQ: ↑ 37.1% shares (2026Q1 vs prior)
396 institutional holders · 242.19M shares
#1 VANGUARD CAPITAL MANAGEMENT LLC 30.26M shares
#2 BlackRock, Inc. 26.35M shares
#3 STATE STREET CORP 17.71M shares
+ 17 more holders Sign up free to view →

📉 Short Interest

Short Interest131.83M
Days to Cover8.7
% of Float33.5%
FINRA data as of Jun 30, 2026

📁 Recent SEC Activity

xbrl XBRL WARRANT Dec 31, 2025
xbrl XBRL CONVERTIBLE Dec 31, 2025
4 INSIDER TRANSACTION Jun 26, 2026
4 INSIDER TRANSACTION Jun 10, 2026
4 INSIDER TRANSACTION Jun 10, 2026
Full SEC filing analysis available with free account →

📰 Recent News

IBRX Stock Climbs Premarket Despite Investor Stake Cut — Retail Sees ‘Imminent’ Stocktwits · Jul 14
Can IBRX Stock Keep Its Pulse? Institutional Investors Buy In, Retail Hopes For Stocktwits · Jul 10
IBRX Stock Slips Overnight: Insider Sale Tests Retail Optimism Ahead Of FDA Grow Stocktwits · Jul 06

📋 What This Means for IBRX Shareholders

ImmunityBio, Inc. (IBRX) has a DilutionScore of 35/100, rated Medium dilution risk. This tier indicates some dilution exposure — often an older shelf registration with remaining capacity, warrants not yet exercised, or a cash position that will require monitoring over the next several quarters. Score as of July 14, 2026.

Cash runway is a key watch item: IBRX has approximately 13 months of runway at current burn rate. Companies with less than 18 months of runway are statistically more likely to file new shelf registrations or ATM programs within the next two quarters. DilutionWatch monitors SEC 10-Q filings to update this estimate each quarter.

DilutionWatch tracks over 25 SEC filing types for IBRX in real-time, scanning EDGAR every 60 seconds. The DilutionWatch screener shows real-time score changes for IBRX alongside comparable medium-risk stocks. Not financial advice — this analysis is for informational purposes only.

Track IBRX Dilution Risk in Real-Time
Get instant alerts when SEC filings impact dilution risk. Free tier available.
Start Tracking IBRX — Free
Real-time SEC alerts DilutionScore™ tracking No credit card required

🔗 Related Stocks — MEDIUM Risk

Other MEDIUM dilution risk stocks tracked by DilutionWatch with similar profiles:

AAT ACH AHRT ALOT AMPH

Browse all 7,800+ tracked stocks →

📖 Dilution Education
→ Complete Dilution Guide for Retail Investors → Anti-Dilution Provisions Explained → Stock Dilution Red Flags to Watch → Understanding Shelf Registrations
🔬 More Research for IBRX
📊 IBRX FDA Catalyst Timeline & Biotech Grade — BiotechSigns 📡 IBRX Signal Convergence & Dark Pool Activity — StonkWhisper

Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.